Raiffeisen Bank International AG Reduces Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Raiffeisen Bank International AG reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 58.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 6,989 shares of the medical equipment provider’s stock after selling 9,670 shares during the period. Raiffeisen Bank International AG’s holdings in Zimmer Biomet were worth $649,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of ZBH. Vanguard Group Inc. raised its holdings in shares of Zimmer Biomet by 0.7% in the first quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock worth $2,609,130,000 after buying an additional 166,763 shares during the last quarter. Dodge & Cox grew its holdings in shares of Zimmer Biomet by 2.3% during the first quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock valued at $2,214,305,000 after buying an additional 446,018 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Zimmer Biomet by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock valued at $465,480,000 after acquiring an additional 69,485 shares during the period. Ameriprise Financial Inc. raised its stake in Zimmer Biomet by 236.0% in the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after acquiring an additional 3,208,596 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Zimmer Biomet by 251.3% during the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after acquiring an additional 1,488,918 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Sunday. Raymond James Financial upped their target price on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Evercore ISI reduced their price target on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research report on Tuesday, October 7th. Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Finally, Barclays dropped their price objective on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $109.00.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $89.10 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 52 week low of $85.33 and a 52 week high of $114.44. The stock’s 50-day moving average price is $97.95 and its 200-day moving average price is $96.84. The stock has a market capitalization of $17.66 billion, a PE ratio of 21.68, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. During the same quarter in the prior year, the firm posted $1.74 EPS. Zimmer Biomet’s quarterly revenue was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend was Tuesday, September 30th. Zimmer Biomet’s payout ratio is presently 23.76%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.39% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.